HOME Research Insight The Jackson Laboratory, Taconic Biosciences, Inc., and Horizon Discovery Group plc to Dominate the Global Humanized Mouse Model Market



The Jackson Laboratory, Taconic Biosciences, Inc., and Horizon Discovery Group plc to Dominate the Global Humanized Mouse Model Market


A number of key players are competing against each other in order to expand their existing customer base. In 2015, the cell-based humanized mouse model market was dominated by The Jackson Laboratory (U.S.) and Taconic Biosciences, Inc. (U.S.). These companies jointly accounted for a share of ~70% to the global cell-based humanized mouse model market in 2015. Furthermore, the genetic humanized mouse model market was dominated by Horizon Discovery Group plc (U.K.) and Taconic Biosciences, Inc. (U.S.). These companies jointly accounted for a share of ~40% to the global genetic humanized mouse model market in 2015. Other players in this market include Harbour Antibodies BV (China), HuMurine Technologies, Inc. (U.S.), Vitalstar Biotechnology Co. Ltd. (China), Crown Bioscience, Inc. (U.S.), ingenious targeting laboratory (U.S.), Axenis S.A.S (France), TRANS GENIC, Inc. (Japan), and genOway S.A. (France).

In 2015, The Jackson Laboratory accounted for a share of ~50.1% in the global cell-based humanized mouse model market. The company receives a large number of grants that support the development of its humanized mouse model business. From 2013 to 2016, the company received more than 15 grants/funds from leading health organizations, academic institutes, and government bodies such as National Institutes of Health (NIH) (U.S.), Howard Hughes Medical Institute (HHMI) (U.S.), Jane’s Trust (U.S.), Government of South Korea, Cogswell Rossi Foundation (U.S.), Maine Cancer Foundation (U.S.), Chordoma Foundation (U.S.), and National Human Genome Research Institute (U.S.). The firm also provides scientific resources, techniques, software, and data to researchers from all over the globe. Wide distribution network and extensive range of humanized mouse strains such as PBMC, CD34, and BLT models, position the firm as one of the major players in the cell-based humanized mouse model market.

In 2015, Taconic Biosciences, Inc. accounted for a share of ~20% in the global cell-based humanized mouse model market and ~11.6% in the global genetic humanized mouse model market. Taconic focuses on agreements, strategic partnerships, and distribution agreements as a key strategy for the growth of its business. The company enters into agreements and partnerships with complementary companies and institutes that are involved in R&D activities and have requirements for humanized mouse models. These strategies are aimed at increasing its customer base for humanized mouse models. For instance, in March 2015, Taconic Biosciences entered into an agreement with Micell Trading Corporation (Japan). The firm also has other distribution agreements in India, Japan, and Singapore. Broad distribution network and a wide range of mouse strain, positions the firm as one of the major players in the humanized mouse model market.

In 2015, Horizon Discovery Group plc accounted for a share of ~28.9% in the global genetic humanized mouse model market. The company focuses on inorganic growth strategies such as partnerships, agreements, and acquisitions & collaborations to strengthen its product portfolio. For instance, in September 2015, Horizon Discovery entered into an agreement with LakePharma, Inc. (U.S.), a contract research organization (CRO). The terms of the license cover commercial use of a genetically-engineered Chinese Hamster Ovary (CHO) cell line, developed by Horizon and adapted to manufacturing conditions by LakePharma. Moreover, Horizon Discovery Group plc acquired SAGE Labs, Inc. (U.S.). This acquisition helped Horizon to expand its range of genetically engineered preclinical models, which are important for the discovery and development of medicines. With a diversified product portfolio of humanized mouse models which includes PDX models and knockout cell lines, wide geographical reach, and focus on inorganic strategies such as agreements and acquisitions, the company has succeeded in creating a strong foothold in the global genetic humanized mouse model market.

Other players operating in this market adopted the strategy of collaborations, contracts, agreements, partnerships, alliances, acquisitions, expansions, product launches, grants, accreditations, patents, and licensing to increase their customer base across geographies and establish a strong foothold in the market.

Related Reports:

Humanized Mouse Model Market by Type (Genetic, Cell-based (CD34, PBMC, BLT)), Application (Neuroscience, Hematopoiesis, Oncology, Immunology & Infectious diseases) & End User(Pharmaceutical & Biotech Companies, CRO)) - Global Forecast to 2021

Contact:
Mr.Rohan
MarketsandMarkets™
UNIT no 802, Tower no. 7, SEZ
Magarpatta city, Hadapsar
Pune, Maharashtra 411013, India
1-888-600-6441
Email: sales@marketsandmarkets.com

Connect Us

Follow us on LinkedIn  Follow us on Facebook   Follow us on Twitter 
Live Chat Support


US : 1-888-600-6441

Search reports